Rehabilitation & Home-Use Medical Devices: Global Regulation & Registration

For every regulator below we answer the three questions home-care and rehabilitation teams ask first: what class is my device, how long will registration take, and what will it cost. Per-market government fees and timelines live in our pricing calculator.

What are home-use and rehabilitation devices?

Home-use medical devices are devices intended to be operated by patients or caregivers outside a clinical setting — home blood pressure monitors, nebulizers, CPAP machines, glucose meters, and in-home medical alert devices and systems among them. Rehabilitation devices help patients recover or maintain function: powered exoskeletons and gait trainers, functional electrical stimulation, continuous passive motion machines, and therapy and mobility aids. The two categories overlap heavily, because more rehabilitation now happens at home. Retail and reimbursement channels often call this category home medical equipment or, in the US Medicare system, durable medical equipment (DME) — a payment and distribution label defined by CMS, not a regulatory classification: a device's FDA or EU MDR class follows its function and intended use regardless of how it is sold or reimbursed.

Two boundaries matter. First, not everything sold for home health is a regulated device: general wellness and fitness products — most massage guns, activity trackers, and recovery gadgets marketed only for relaxation or fitness — usually fall outside device regulation, while the same hardware with a medical claim does not. Second, home use is a regulatory attribute, not a device type: FDA treats the home as a use environment that adds human-factors and durability requirements on top of a device's normal classification, because the operator is untrained and the setting is uncontrolled. Every jurisdiction draws these lines a little differently, so the same nebulizer or exoskeleton can be a Class II device in the US, a Class IIa device in Europe, and a notification in Brazil. Every cost below has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets.

FDA home-use device regulation (United States)

FDA regulates home-use devices under the same risk-based framework as any other device, then adds a home-use device focus centered on human factors: labeling a patient can actually follow, usability validation with representative users, and durability for an uncontrolled environment. FDA's guidance Design Considerations for Devices Intended for Home Use sets the expectations for environment, user, and labeling analysis that the human-factors file must answer. Classification follows the device's function, not the fact that it is used at home. Home use is not the same as over-the-counter. Many home-use devices remain prescription-only — CPAP machines, for example, are cleared as prescription devices labeled under 21 CFR 801.109 — while others, such as most home blood pressure monitors and OTC TENS units, are cleared for direct-to-consumer sale. The Rx-or-OTC decision shapes the program: OTC demands labeling a lay user can follow without a clinician and stronger usability validation, sometimes targets a different product code (FDA keeps separate prescription and OTC TENS classifications), and a later Rx-to-OTC switch generally means a new 510(k).

• Classification. Most home-use and rehabilitation devices are Class II and clear through a 510(k): home blood pressure monitors, nebulizers, CPAP, and powered exoskeletons. Simple aids such as canes, crutches, and elastic supports are typically Class I, and continuous passive motion machines are also Class I and 510(k)-exempt as powered exercise equipment (21 CFR 890.5380). Novel functions without a predicate go De Novo, and products marketed purely for general wellness or fitness — many percussive massage guns among them — often sit outside device regulation entirely until a medical claim pulls them back in.
• Timeline. A 510(k) typically runs 3 to 9 months end to end including preparation and FDA interaction; a De Novo for a first-of-kind device such as an early exoskeleton plans for 9 to 15 months. A Pre-Submission meeting adds a few weeks up front and usually saves review cycles, especially on the human-factors file.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Powered exoskeletons and rehabilitation robotics

Powered exoskeletons — the medical exoskeletons in the news — are the highest-profile rehabilitation devices in search, and they are also the clearest example of how a novel category earns its class. FDA created the powered lower-extremity exoskeleton classification through De Novo and placed it in Class II with special controls, so first-of-kind devices cleared the novel path and follow-on exoskeletons now use a 510(k) against that classification. Gait-training exoskeletons, functional electrical stimulation, and rehabilitation robots — the "new devices helping stroke and spinal-cord-injury patients" that drive much of this interest — are cleared for use in rehabilitation clinics and, for some models, personal use at home. Human-factors evidence is central, because the operator may be a patient or a family caregiver rather than a clinician.

Start from our United States market page for the full FDA pathway.

EU MDR classification for home-use and rehabilitation devices (CE marking)

Under the EU Medical Device Regulation (MDR 2017/745), classification runs through the Annex VIII rules and a notified body sits in the middle of your timeline for anything above Class I. Home use adds a specific evidence layer: usability engineering to IEC 62366 and, for electrical devices, the home-healthcare collateral standard IEC 60601-1-11.

• Classification. Most active home-use and rehabilitation devices land in Class IIa, with therapeutic devices that administer or exchange energy in a potentially hazardous way reaching IIb. Non-active mobility aids and simple supports can be Class I, some of them self-certified. Powered exoskeletons and rehabilitation robots are active devices and generally sit at IIa or IIb depending on their function.
• Timeline. Plan 9 to 18 months with a notified body for a first Class IIa certification, driven by notified body capacity and the maturity of your technical documentation and clinical evaluation. Genuine Class I devices you can self-certify move much faster.
• Cost. There is no central government fee; the money goes to the notified body — typically €30,000 to €70,000 across a first Class IIa certification cycle, plus annual surveillance — and to building MDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

See the European Union market page for the MDR route and notified body strategy.

Home-use device registration in Brazil and Latin America (ANVISA)

Brazil anchors any Latin American strategy, and ANVISA classifies devices into risk Classes I to IV on the IMDRF model. Mexico's COFEPRIS is the region's second gate. Both require a local representative — we act as Brazil Registration Holder without taking control of your registration.

• Classification. Lower-risk home devices such as blood pressure monitors and nebulizers usually fall in Class I or II and take the streamlined notification (notificação) route; Class III-IV devices require full registration (registro) with deeper technical evidence.
• Timeline. Notification is typically a matter of weeks; Class III-IV registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months on the standard route, faster where reliance on an FDA or CE approval applies.
• Cost. ANVISA government fees: R$1,406 to notify a Class I-II product; Class III-IV family registration runs R$8,510 to R$19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499 to MX$30,798 per product by class. Our registration service starts at US$2,000 per year (US$3,000 for high-risk classes).

Start with the Brazil market page; labeling and instructions for use are prepared natively in Portuguese and Spanish.

Home-use device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas teams enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a good FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN — Malaysia, Thailand, Indonesia, Vietnam, the Philippines — where reliance-friendly frameworks make each additional market incremental. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry — local type testing and the longest timelines — so treat it as its own program when the business case justifies it, not a default stop.

• Classification. Singapore's HSA uses risk Classes A through D, and most home-use devices sit at A or B; ASEAN members track the same IMDRF-style model. Japan classifies against JMDN codes, Korea's MFDS uses Classes I-IV, and China places most active home and rehabilitation devices in Class II.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the same dossier. Most Class II home-use devices with a certification standard clear Japan's Ninsho certification through a Registered Certification Body in roughly 4 to 8 months, while devices without a standard go to PMDA Shonin review at 9 to 14 months. Korea runs 6 to 12 months including KGMP, and China 12 to 24 months including type testing.
• Cost. Singapore government fees are light: a SGD 560 application plus SGD 2,010 to SGD 6,250 evaluation by class. ASEAN peers are similar (Malaysia MYR 500 to MYR 3,750; Thailand THB 3,100 to THB 74,000). Japan's PMDA Shonin review fees start around ¥1 million, while Ninsho certification fees are paid to the Registered Certification Body; China's NMPA fees for imported Class II-III run roughly RMB 210,000 to RMB 310,000 before type testing. Our registration service starts at US$2,000 per year across Singapore and ASEAN; China, Japan, and Korea are quoted flat per market on the same model.

See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Home-use device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing markets in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work if the dossier is assembled correctly. SFDA regulates medical devices on the IMDRF model and requires a local Authorized Representative.

• Classification. SFDA classifies devices into risk Classes A through D, mirroring your reference-market class in most cases; the UAE's MOHAP and other MENA authorities lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest — generally a few thousand US dollars' equivalent per authority — so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages.

Evidence, quality system, and lifecycle

Home use is, above all, a usability problem: the operator is often an older adult, a patient with impaired function, or an untrained caregiver, and the setting is a living room rather than a ward. Every major regulator now expects usability engineering to IEC 62366 with validation on representative users, and electrical home devices carry the home-healthcare collateral standard IEC 60601-1-11 on top of IEC 60601-1. We set up ISO 13485 and FDA QMSR processes, plan human-factors and clinical evidence once for reuse across FDA, EU MDR, and APAC submissions, and — for connected home monitors and alert devices that send data to clinicians or apps — maintain cybersecurity documentation that satisfies FDA, EU MDR, and IEC 81001-5-1. After launch, complaint handling, vigilance, and change assessments keep every registration current.

One program, every major market

A global home-care and rehabilitation program is a sequencing problem: pick the anchor market, build the human-factors and clinical file once, and reuse classification analyses, evidence, and QMS artifacts everywhere else. We run the full program from a single team — strategy, submissions, in-country representation, and post-market maintenance — with transparent government fees and timelines in our pricing calculator.